Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET
Company Participants
Gail Cohen – Vice President-Corporate Communications
Rick Winningham – Chairman and Chief Executive Officer
Rhonda Farnum – Senior Vice President and Chief Business Officer
Rick Graham – Senior Vice President-Research and Development
Andrew Hindman – Chief Financial Officer
Conference Call Participants
Eva Privitera – Cowen
Ben Ricard – Needham & Company
David Risinger – SVB Securities
Operator
Ladies and gentlemen, good afternoon. I’d like to welcome everyone to the Theravance Biopharma First Quarter 2022 Conference Call. [Operator Instructions] Also, today’s conference call is being recorded.
And now I would like to turn the call over to Gail Cohen, Vice President, Corporate Communications. Please go ahead.
Gail Cohen
Good afternoon, and thank you for joining the Theravance Biopharma First Quarter 2022 Conference Call to discuss our business. As always, I remind you that this call will contain forward-looking statements that involve risks and uncertainties, including statements about our development pipeline, expected benefits of our products, anticipated timing of clinical trials, regulatory filings and expected financial results. Information concerning factors that could cause results to differ materially from our forward-looking statements is discussed further in our filings with the SEC.
I would direct your attention to Slide 3. Joining us are Rick Winningham, Chief Executive Officer; followed by Rhonda Farnum, Senior Vice President and Chief Business Officer; Rick Graham, Senior Vice President, Research and Development; and Andrew Hindman, Chief Financial Officer.
Now, I will hand the call to Rick Winningham for opening remarks.
Rick Winningham
Thanks, Gail. And turning to Slide 4. Last September, we announced the restructuring of the company to optimize our business. Since then, we’ve rapidly transitioned to a focused and streamlined Theravance Biopharma. We’re focused on leveraging our expertise in developing and commercializing respiratory therapeutics. We’ve streamlined our R&D investments to concentrate on highest value opportunities, and we’re exploring strategic partnerships for our pipeline assets to unlock additional value. All of these actions drive towards our goal to maximize shareholder value.
There are three key pillars of value creation, as highlighted on Slide 5 for the go-forward plan that builds on our proven record of respiratory innovation supporting several approved medicines for COPD and asthma. These pillars include YUPELRI, which was discovered and developed by Theravance Biopharma, is commercialized in partnership with Viatris. YUPELRI has continued quarter-over-quarter market share growth despite the respiratory pandemic. Sell-side analysts covering Theravance Biopharma estimate YUPELRI has the potential to generate U.S. peak sales of approximately $400 million annually.